FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Stroup

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Activities & Behaviors

Schizophrenic Psychology

Procedures

Geographic Areas

United States

Organizations

National Institute of Mental Health (U.S.)

Co-author Network

Publications

TOP 3
Thomas Stroup; Matthew J Byerly; Ira D Glick; Ahsan Y Khan; J Steven Lamberti; Joseph P McEvoy; Henry A Nasrallah; Neepa Ray; Richard M Steinbook; Robert M Hamer
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.
Richard S E Keefe; Stephen M Marder; Alice Medalia; Stephen J Olson; Jayendra K Patel; Peter F Buckley; Stanley N Caroff; D Cyril D'Souza; Karen A Graham; Adam J Haim; Robert M Hamer; Philip D Harvey; Dawn I Velligan; Sophia Vinogradov; Trina M Walker; Del D Miller; Thomas Stroup
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.
Nancy H Covell; Susan M Essock; Carlos T Jackson; Joseph P McEvoy; Ingrid A Rojas; Nina R Schooler; Thomas Stroup
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Stroup (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Thomas Stroup; Matthew J Byerly; Ira D Glick; Ahsan Y Khan; J Steven Lamberti; Joseph P McEvoy; Henry A Nasrallah; Neepa Ray; Richard M Steinbook; Robert M Hamer
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.
Schizophrenia research 2013;146(1-3):190-5.
2012: Richard S E Keefe; Stephen M Marder; Alice Medalia; Stephen J Olson; Jayendra K Patel; Peter F Buckley; Stanley N Caroff; D Cyril D'Souza; Karen A Graham; Adam J Haim; Robert M Hamer; Philip D Harvey; Dawn I Velligan; Sophia Vinogradov; Trina M Walker; Del D Miller; Thomas Stroup
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.
The Journal of clinical psychiatry 2012;73(7):1016-22.
2012: Nancy H Covell; Susan M Essock; Carlos T Jackson; Joseph P McEvoy; Ingrid A Rojas; Nina R Schooler; Thomas Stroup
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
The Journal of clinical psychiatry 2012;73(5):669-75.
2012: Eric D A Hermes; Daniel Sokoloff; Thomas Stroup; Robert A Rosenheck
Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
The Journal of clinical psychiatry 2012;73(4):526-32.
2011: Karin E Kerfoot; Joseph P McEvoy; Ismene L Petrakis; Robert A Rosenheck; Thomas Stroup; Marvin S Swartz; Richard S E Keefe
Substance use and schizophrenia: adverse correlates in the CATIE study sample.
Schizophrenia research 2011;132(2-3):177-82.
2011: Thomas Stroup; Marvin S Swartz; Robert H Hamer; Lisa M LaVange; Jeffrey A Lieberman; Joseph P McEvoy; Abraham M Nussbaum; Diana O Perkins; Kimberly D Ring; Robert A Rosenheck
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
The American journal of psychiatry 2011;168(9):947-56.
2011: Richard S E Keefe; Stephen R Marder; Alice Medalia; Steven M Silverstein; Morris D Bell; Dwight Dickinson; Joseph Ventura; Sophia Vinogradov; Thomas Stroup
Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia.
Schizophrenia bulletin 2011;37(5):1057-65.
2011: Cheryl L P Vigen; Ling Zheng; Thomas Stroup; David L Sultzer; Pierre N. Tariot; Karen S Dagerman; John K Hsiao; Richard S E Keefe; Barry D Lebowitz; Constantine G Lyketsos; Wendy J Mack; Mary Sano; Lon S Schneider
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
The American journal of psychiatry 2011;168(8):831-9.
2011: Susan M Essock; Carlos Jackson; Joseph P McEvoy; Ingrid Rojas; Nina R Schooler; Thomas Stroup; Nancy H Covell
Effectiveness of switching from antipsychotic polypharmacy to monotherapy.
The American journal of psychiatry 2011;168(7):702-8.
2011: Eric Hermes; Henry Nasrallah; Vicki Davis; Jonathan Meyer; Joseph McEvoy; Donald Goff; Sonia Davis; Thomas Stroup; Marvin Swartz; Jeffrey Lieberman; Robert Rosenheck
The association between weight change and symptom reduction in the CATIE schizophrenia trial.
Schizophrenia research 2011;128(1-3):166-70.
2010: Thomas I Konneker; James J Crowley; Corey R Quackenbush; Richard S E Keefe; Diana O Perkins; Thomas Stroup; Jeffrey A Lieberman; Edwin J C G van den Oord; Patrick F Sullivan
No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2010;153B(5):1115-7.
2010: Huei-Ting Tsai; Stanley N Caroff; Joseph McEvoy; Jeffrey A Lieberman; Kari E North; Thomas Stroup; Del D Miller; Patrick F Sullivan
A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2010;153B(1):336-40.
2009: Jonathan M Meyer; Joseph P McEvoy; Vicki G Davis; Donald C Goff; Henry A Nasrallah; Sonia M Davis; John K Hsiao; Marvin S Swartz; Thomas Stroup; Jeffrey A Lieberman
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
Biological psychiatry 2009;66(11):1013-22.
2009: Shane E McCarthy; Vladimir Makarov; George Kirov; Anjene M Addington; Jon McClellan; Seungtai Yoon; Diana O Perkins; Diane E Dickel; Mary Kusenda; Olga Krastoshevsky; Verena Krause; Ravinesh A Kumar; Detelina Grozeva; Dheeraj Malhotra; Tom Walsh; Elaine H Zackai; Paige Kaplan; Jaya Ganesh; Ian D Krantz; Nancy B Spinner; Patricia Roccanova; Abhishek Bhandari; Kevin Pavon; B Lakshmi; Anthony Leotta; Jude Kendall; Yoon-Ha Lee; Vladimir Vacic; Sydney Gary; Lilia M Iakoucheva; Timothy J Crow; Susan L Christian; Jeffrey A Lieberman; Thomas Stroup; Terho Lehtimäki; Kaija Puura; Chad Haldeman-Englert; Justin Pearl; Meredith Goodell; Virginia L Willour; Pamela Derosse; Jo Steele; Layla Kassem; Jessica Wolff; Nisha Chitkara; Francis McMajon; Anil Malhotra; James B Potash; Thomas G. Schulze; Markus M Nöthen; Sven Cichon; Marcella Rietschel; Ellen Leibenluft; Vlad Kustanovich; Clara M Lajonchere; James S Sutcliffe; David Skuse; Michael Gill; Louise Gallagher; Nancy R Mendell; Nick Craddock; Michael J Owen; Michael C O'Donovan; Tamim H Shaikh; Ezra Susser; Lynn E Delisi; Patrick F Sullivan; Curtis K Deutsch; Judith Rapoport; Deborah Levy; Mary-Claire King; Jonathan Sebat
Microduplications of 16p11.2 are associated with schizophrenia.
Nature genetics 2009;41(11):1223-7.
2009: Ling Zheng; Wendy Mack; Karen S Dagerman; John K Hsiao; Barry D Lebowitz; Constantine G Lyketsos; Thomas Stroup; David L Sultzer; Pierre N. Tariot; Cheryl Vigen; Lon S Schneider
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.
The American journal of psychiatry 2009;166(5):583-90.
2009: Lydia A Chwastiak; Robert A Rosenheck; Joseph P McEvoy; Thomas Stroup; Marvin S Swartz; Sonia M Davis; Jeffrey A Lieberman
The impact of obesity on health care costs among persons with schizophrenia.
General hospital psychiatry 2009;31(1):1-7.
2009: Thomas Stroup; Jeffrey A Lieberman; Joseph P McEvoy; Sonia M Davis; Marvin Swartz; Richard S E Keefe; Alexander Miller; Robert A Rosenheck; John K Hsiao
Results of phase 3 of the CATIE schizophrenia trial.
Schizophrenia research 2009;107(1):1-12.
2008: James J Crowley; Richard S E Keefe; Diana O Perkins; Thomas Stroup; Jeffrey A Lieberman; Patrick F Sullivan
The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2008;147B(7):1298-300.
2008: Del D Miller; Stanley N Caroff; Sonia M Davis; Robert A Rosenheck; Joseph P McEvoy; Bruce L Saltz; Silvana Riggio; Miranda Chakos; Marvin S Swartz; Richard S E Keefe; Thomas Stroup; Jeffrey A Lieberman
Extrapyramidal side-effects of antipsychotics in a randomised trial.
The British journal of psychiatry : the journal of mental science 2008;193(4):279-88.
2008: Gail L Daumit; Donald C Goff; Jonathan M Meyer; Vicki G Davis; Henry A Nasrallah; Joseph P McEvoy; Robert Rosenheck; Sonia M Davis; John K Hsiao; Thomas Stroup; Jeffrey A Lieberman
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
Schizophrenia research 2008;105(1-3):175-87.
2008: Jonathan M Meyer; Vicki G Davis; Joseph P McEvoy; Donald C Goff; Henry A Nasrallah; Sonia M Davis; Gail L Daumit; John Hsiao; Marvin S Swartz; Thomas Stroup; Jeffrey A Lieberman
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
Schizophrenia research 2008;103(1-3):104-9.
2008: Jeffrey Swanson; Marvin Swartz; Richard A Van Dorn; Jan Volavka; John Monahan; Thomas Stroup; Joseph P McEvoy; H Ryan Wagner; Eric Elbogen; Jeffrey A Lieberman
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia.
The British journal of psychiatry : the journal of mental science 2008;193(1):37-43.
2008: Patrick F Sullivan; Danyu Lin; J-Y Tzeng; Edwin J C G van den Oord; Diana O Perkins; Thomas Stroup; Michael Wagner; S Lee; Fred A Wright; Fei Zou; W Liu; A M Downing; J Lieberman; S L Close
Genomewide association for schizophrenia in the CATIE study: results of stage 1.
Molecular psychiatry 2008;13(6):570-84.
2008: Marvin Swartz; Thomas Stroup; Joseph P McEvoy; Sonia M Davis; Robert A Rosenheck; Richard S E Keefe; John K Hsiao; Jeffrey A Lieberman
What CATIE found: results from the schizophrenia trial.
Psychiatric services (Washington, D.C.) 2008;59(5):500-6.
2008: Abraham M Nussbaum; Thomas Stroup
Paliperidone for treatment of schizophrenia.
Schizophrenia bulletin 2008;34(3):419-22.
2008: Jonathan M Meyer; Vicki G Davis; Donald C Goff; Joseph P McEvoy; Henry A Nasrallah; Sonia M Davis; Robert A Rosenheck; Gail L Daumit; John Hsiao; Marvin S Swartz; Thomas Stroup; Jeffrey A Lieberman
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.
Schizophrenia research 2008;101(1-3):273-86.
2008: Sandra G Resnick; Robert A Rosenheck; Jose M Canive; Cyril De Souza; Thomas Stroup; Joseph McEvoy; Sonia M Davis; Richard S E Keefe; Marvin Swartz; Jeffrey Lieberman
Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.
The journal of behavioral health services & research 2008;35(2):215-25.
2008: Thomas Stroup; John R Geddes
Randomized controlled trials for schizophrenia: study designs targeted to distinct goals.
Schizophrenia bulletin 2008;34(2):266-74.
2008: Marvin Swartz; H Ryan Wagner; Jeffrey Swanson; Thomas Stroup; Joseph P McEvoy; Frederick W Reimherr; Del D Miller; Mark McGee; Ahsan Khan; Jose M Canive; Sonia M Davis; John K Hsiao; Jeffrey A Lieberman
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Schizophrenia research 2008;100(1-3):39-52.
2008: A Nussbaum; Thomas Stroup
Paliperidone for schizophrenia.
Cochrane database of systematic reviews (Online) 2008;(2):CD006369.
2008: Daniel B Campbell; Philip J Ebert; Tara Skelly; Thomas Stroup; Jeffrey Lieberman; Pat Levitt; Patrick F Sullivan
Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.
Biological psychiatry 2008;63(1):32-41.
2007: Troy A Moore; Robert W Buchanan; Peter F Buckley; John A Chiles; Robert R Conley; M Lynn Crismon; Susan M Essock; Molly Finnerty; Stephen R Marder; Joseph P McEvoy; Delbert Robinson; Nina R Schooler; Steven P Shon; Thomas Stroup; Del D Miller; Alexander Miller
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.
The Journal of clinical psychiatry 2007;68(11):1751-62.
2007: Mahesh B Jayaram; Prakash M Hosalli; Thomas Stroup
Risperidone versus olanzapine for treatment of schizophrenia.
Schizophrenia bulletin 2007;33(6):1274-6.
2007: Scott Y H Kim; Paul S Appelbaum; Jeffrey Swan; Thomas Stroup; Joseph P McEvoy; Donald C Goff; Dilip V Jeste; J Steven Lamberti; Adrian Leibovici; Eric D Caine
Determining when impairment constitutes incapacity for informed consent in schizophrenia research.
The British journal of psychiatry : the journal of mental science 2007;191():38-43.
2007: Richard S E Keefe; Robert Bilder; Sonia M Davis; Philip D Harvey; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; George Capuano; Thomas Stroup; Joseph P McEvoy; Marvin Swartz; Robert A Rosenheck; Diana O Perkins; Clarence E Davis; John K Hsiao; Jeffrey A Lieberman
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Archives of general psychiatry 2007;64(6):633-47.
2007: Robert Rosenheck; Marvin Swartz; Joseph McEvoy; Thomas Stroup; Sonia Davis; Richard Se Keefe; John Hsiao; Jeffrey Lieberman
Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial.
Expert review of pharmacoeconomics & outcomes research 2007;7(2):103-11.
2007: Thomas Stroup
Heterogeneity of treatment effects in schizophrenia.
The American journal of medicine 2007;120(4 Suppl 1):S26-31.
2007: Patrick F Sullivan; Richard S E Keefe; Leslie A Lange; Ethan M Lange; Thomas Stroup; Jeffrey Lieberman; Patricia F Maness
NCAM1 and neurocognition in schizophrenia.
Biological psychiatry 2007;61(7):902-10.
2007: Marvin Swartz; Diana O Perkins; Thomas Stroup; Sonia M Davis; George Capuano; Robert A Rosenheck; Frederick W Reimherr; Mark F McGee; Richard S E Keefe; Joseph P McEvoy; John K Hsiao; Jeffrey A Lieberman
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
The American journal of psychiatry 2007;164(3):428-36.
2007: Thomas Stroup; Jeffrey A Lieberman; Joseph P McEvoy; Marvin Swartz; Sonia M Davis; George Capuano; Robert A Rosenheck; Richard S E Keefe; Alexander Miller; Irving Belz; John K Hsiao
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
The American journal of psychiatry 2007;164(3):415-27.
2007: Andréa Poyastro Pinheiro; Richard S E Keefe; Tara Skelly; Megan Olarte; Keren Leviel; Leslie A Lange; Ethan M Lange; Thomas Stroup; Jeffrey Lieberman; Patrick F Sullivan
AKT1 and neurocognition in schizophrenia.
The Australian and New Zealand journal of psychiatry 2007;41(2):169-77.
2006: Susan M Essock; Nancy H Covell; Sonia M Davis; Thomas Stroup; Robert A Rosenheck; Jeffrey A Lieberman
Effectiveness of switching antipsychotic medications.
The American journal of psychiatry 2006;163(12):2090-5.
2006: Robert A Rosenheck; Douglas L Leslie; Jody Sindelar; Edward A Miller; Haiqun Lin; Thomas Stroup; Joseph McEvoy; Sonia M Davis; Richard S E Keefe; Marvin Swartz; Diana O Perkins; John K Hsiao; Jeffrey Lieberman
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
The American journal of psychiatry 2006;163(12):2080-9.
2006: Clive E Adams; Prathap Tharyan; Evandro Silva Freire Coutinho; Thomas Stroup
The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries.
The British journal of psychiatry : the journal of mental science 2006;189():391-2.
2006: Lon S Schneider; Pierre N. Tariot; Karen S Dagerman; Sonia M Davis; John K Hsiao; M Saleem Ismail; Barry D Lebowitz; Constantine G Lyketsos; J Michael Ryan; Thomas Stroup; David L Sultzer; Daniel Weintraub; Jeffrey A Lieberman
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
The New England journal of medicine 2006;355(15):1525-38.
2006: Henry A Nasrallah; Jonathan M Meyer; Donald C Goff; Joseph P McEvoy; Sonia M Davis; Thomas Stroup; Jeffrey A Lieberman
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.
Schizophrenia research 2006;86(1-3):15-22.
2006: Richard S E Keefe; Robert Bilder; Philip D Harvey; Sonia M Davis; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; Del D Miller; Jose M Canive; Lawrence W Adler; Theo C Manschreck; Marvin Swartz; Robert Rosenheck; Diana O Perkins; Trina M Walker; Thomas Stroup; Joseph P McEvoy; Jeffrey A Lieberman
Baseline neurocognitive deficits in the CATIE schizophrenia trial.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006;31(9):2033-46.
2006: L Citrome; Thomas Stroup
Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?
International journal of clinical practice 2006;60(8):933-40.
2006: Marvin Swartz; H Ryan Wagner; Jeffrey Swanson; Thomas Stroup; Joseph P McEvoy; Mark McGee; Del D Miller; Frederick W Reimherr; Ahsan Khan; Jose M Cañive; Jeffrey A Lieberman
Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study.
Psychiatric services (Washington, D.C.) 2006;57(8):1110-6.
2006: Thomas Stroup
Review: higher rates of attrition in antipsychotic treatment arms of placebo controlled trials than in trials with active comparators.
Evidence-based mental health 2006;9(3):70.
2006: Jeffrey Swanson; Marvin Swartz; Richard A Van Dorn; Eric Elbogen; H Ryan Wagner; Robert A Rosenheck; Thomas Stroup; Joseph P McEvoy; Jeffrey A Lieberman
A national study of violent behavior in persons with schizophrenia.
Archives of general psychiatry 2006;63(5):490-9.
2006: Thomas Stroup; Jeffrey A Lieberman; Joseph P McEvoy; Marvin Swartz; Sonia M Davis; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Clarence E Davis; Joanne B Severe; John K Hsiao
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
The American journal of psychiatry 2006;163(4):611-22.
2006: Joseph P McEvoy; Jeffrey A Lieberman; Thomas Stroup; Sonia M Davis; Herbert Y Meltzer; Robert A Rosenheck; Marvin Swartz; Diana O Perkins; Richard S E Keefe; Clarence E Davis; Joanne B Severe; John K Hsiao
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
The American journal of psychiatry 2006;163(4):600-10.
2006: Marvin Swartz; H Ryan Wagner; Jeffrey Swanson; Thomas Stroup; Joseph P McEvoy; Jose M Canive; Del D Miller; Frederick W Reimherr; Mark McGee; Ahsan Khan; Richard A Van Dorn; Robert A Rosenheck; Jeffrey A Lieberman
Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study.
The Journal of nervous and mental disease 2006;194(3):164-72.
2006: Thomas Stroup; Wayne Alves; Robert M Hamer; Jeffrey A Lieberman
Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.
Nature reviews. Drug discovery 2006;5(2):133-46.
2006: Thomas Stroup; Paul S Appelbaum
Evaluation of "subject advocate" procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study.
Schizophrenia bulletin 2006;32(1):147-52.
2005: Donald C Goff; Lisa M Sullivan; Joseph P McEvoy; Jonathan M Meyer; Henry A Nasrallah; Gail L Daumit; Steven Lamberti; Ralph B D'Agostino; Thomas Stroup; Sonia M Davis; Jeffrey A Lieberman
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.
Schizophrenia research 2005;80(1):45-53.
2005: Del D Miller; Joseph P McEvoy; Sonia M Davis; Stanley N Caroff; Bruce L Saltz; Miranda Chakos; Marvin S Swartz; Richard S E Keefe; Robert A Rosenheck; Thomas Stroup; Jeffrey A Lieberman
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
Schizophrenia research 2005;80(1):33-43.
2005: Jonathan M Meyer; Henry A Nasrallah; Joseph P McEvoy; Donald C Goff; Sonia M Davis; Miranda Chakos; Jayendra K Patel; Richard S E Keefe; Thomas Stroup; Jeffrey A Lieberman
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
Schizophrenia research 2005;80(1):9-18.
2005: H Stephen Leff; Dow A Wieman; Bentson H McFarland; Joseph P Morrissey; Aileen B Rothbard; David Shern; A Michael Wylie; Roger A Boothroyd; Thomas Stroup; I Elaine Allen
Assessment of Medicaid managed behavioral health care for persons with serious mental illness.
Psychiatric services (Washington, D.C.) 2005;56(10):1245-53.
2005: Jeffrey A Lieberman; Thomas Stroup; Joseph P McEvoy; Marvin Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne B Severe; John K Hsiao
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
The New England journal of medicine 2005;353(12):1209-23.
2005: Aileen B Rothbard; Mary Rose Murrin; Neil Jordan; Eri Kuno; Bentson H McFarland; Thomas Stroup; Joseph P Morrissey; Paul G Stiles; Roger A Boothroyd; Elizabeth Merwin; David Shern
Effects of antipsychotic medication on psychiatric service utilization and cost.
The journal of mental health policy and economics 2005;8(2):83-93.
2005: Julie Markham; K P McKian; Thomas Stroup; Janice M Juraska
Sexually dimorphic aging of dendritic morphology in CA1 of hippocampus.
Hippocampus 2005;15(1):97-103.
2004: Daniel W Bradford; Thomas Stroup
Schizophrenia, drug therapy, and monitoring.
The New England journal of medicine 2004;350(4):415-6.
2004: Thomas Stroup; Joseph P McEvoy; Jeffrey A Lieberman
Revised PORT recommendations.
Schizophrenia bulletin 2004;30(3):609-11.
2003: Jeffrey A Lieberman; Thomas Stroup
Schizophrenia, VI: Treatments.
The American journal of psychiatry 2003;160(10):1748.
2003: Marvin Swartz; Diana O Perkins; Thomas Stroup; Joseph P McEvoy; Jennifer M Nieri; David C Haak
Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.
Schizophrenia bulletin 2003;29(1):33-43.
2003: Thomas Stroup; Joseph P McEvoy; Marvin Swartz; Matthew J Byerly; Ira D Glick; Jose M Canive; Mark F McGee; George M Simpson; Michael C Stevens; Jeffrey A Lieberman
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.
Schizophrenia bulletin 2003;29(1):15-31.
2003: Jeffrey A Lieberman; Thomas Stroup
Guest editors' introduction: what can large pragmatic clinical trials do for public mental health care?
Schizophrenia bulletin 2003;29(1):1-6.
2002: Joseph P Morrissey; Thomas Stroup; Alan R Ellis; Elizabeth Merwin
Service use and health status of persons with severe mental illness in full-risk and no-risk medicaid programs.
Psychiatric services (Washington, D.C.) 2002;53(3):293-8.
2001: Thomas Stroup; Joseph P Morrissey; Alan R Ellis; M Blank
Correlates of family burden under medicaid managed mental health care.
Administration and policy in mental health 2001;29(2):117-28.
2000: Thomas Stroup; M S Swartz; J A Lieberman; Joseph P McEvoy
Comparative effectiveness of antipsychotic drugs in schizophrenia.
Dialogues in clinical neuroscience 2000;2(4):373-9.
2000: M R Phillips; Y Li; Thomas Stroup; L Xin
Causes of schizophrenia reported by patients' family members in China.
The British journal of psychiatry : the journal of mental science 2000;177():20-5.
1997: Thomas Stroup
Managed behavioral health care in the public sector.
Harvard review of psychiatry 1997;5(1):47-9.
1996: Thomas Stroup; RA Dorwart; C W Hoover; J Brody
Organized systems of care and psychiatrists' fees.
Psychiatric services (Washington, D.C.) 1996;47(5):461.
1995: Thomas Stroup; RA Dorwart
Impact of a managed mental health program on Medicaid recipients with severe mental illness.
Psychiatric services (Washington, D.C.) 1995;46(9):885-9.